BIO PATH HOLDINGS INC has a total of 55 patent applications. It increased the IP activity by 209.0%. Its first patent ever was published in 2016. It filed its patents most often in United States, Australia and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are LENTIGEN CORP, HUAIAN KANGYILAI STEM CELL BIOTECHNOLOGY CO LTD and CAPRICOR INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 7 | |
#2 | Australia | 6 | |
#3 | EPO (European Patent Office) | 6 | |
#4 | Republic of Korea | 6 | |
#5 | WIPO (World Intellectual Property Organization) | 6 | |
#6 | Canada | 5 | |
#7 | China | 5 | |
#8 | Singapore | 5 | |
#9 | Israel | 3 | |
#10 | Brazil | 2 | |
#11 | Mexico | 2 | |
#12 | Colombia | 1 | |
#13 | Hong Kong | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry | |
#4 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Sugars | |
#5 | Climate change adaptation technologies | |
#6 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Ashizawa Ana Tari | 25 |
#2 | Nielsen Peter | 17 |
#3 | Ashizawa Ana | 14 |
#4 | Andrews David W | 7 |
#5 | Hooper Douglas Craig | 7 |
#6 | Ana Tari Ashizawa | 5 |
#7 | Peter Nielsen | 3 |
Publication | Filing date | Title |
---|---|---|
AU2018255353A1 | P-ethoxy nucleic acids for IGF-1R inhibition | |
US2021123058A1 | P-ethoxy nucleic acids for bcl2 inhibition | |
CN110636836A | P-ethoxy nucleic acids for STAT3 inhibition | |
AU2018254485A1 | P-ethoxy nucleic acids for IGF-1R inhibition | |
CN109963571A | Combination treatment containing liposome antisense oligonucleotides | |
AU2016340123A1 | P-ethoxy nucleic acids for liposomal formulation |